Literature DB >> 18569641

Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.

Elisabetta Capriotti1, Eric C Vonderheid, Christopher J Thoburn, Mariusz A Wasik, David W Bahler, Allan D Hess.   

Abstract

Peripheral blood cells from 28 patients with leukemic cutaneous T-cell lymphoma including 25 patients with Sezary syndrome were evaluated for expression of regulatory T-cell-associated markers (FoxP3, CD25, CTLA-4, neurophilin-1), T-cell activation markers (CD28 and its ligands B7.1 and B7.2) and NK cell-associated markers (NKG2D and its ligands Mic-A and Mic-B) using real-time quantitative polymerase chain reaction. T-plastin served as a positive genetic marker, and its expression correlated to blood tumor burden. More than 90% of samples had transcripts for CD28 and Mic-B, but less than 30% of samples expressed FoxP3, CTLA-4 and CD25. Expression of Mic-B by neoplastic cells could provide another mechanism to inhibit anti-tumor immune responses. FoxP3 expression correlated with a poor prognosis. Although the underlying mechanisms accounting for this correlation remain unclear, the expression of the Foxp3 and CTLA-4 regulatory elements indicates that a subset of leukemic cases displays a regulatory T-cell phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18569641      PMCID: PMC3983987          DOI: 10.1080/10428190802064917

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  92 in total

1.  Regulatory T-cell phenotype in association with large cell transformation of mycosis fungoides.

Authors:  Christian Hallermann; Christoph Niermann; Hans-Joachim Schulze
Journal:  Eur J Haematol       Date:  2007-01-23       Impact factor: 2.997

2.  Is FOXP3 expressed in cutaneous T-cell lymphomas?

Authors:  Alison H Banham; Philip J Brown; Linden Lyne; Hans-Joachim Schulze; Christian Hallermann
Journal:  Eur J Haematol       Date:  2007-11-23       Impact factor: 2.997

3.  CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.

Authors:  Rakhshandra Talpur; Daniel M Jones; Alvaro J Alencar; Narin Apisarnthanarax; Kelly L Herne; Ying Yang; Madeleine Duvic
Journal:  J Invest Dermatol       Date:  2006-03       Impact factor: 8.551

4.  Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.

Authors:  Arturo Molina; Jasmine Zain; Daniel A Arber; Maria Angelopolou; Margaret O'Donnell; Joyce Murata-Collins; Stephen J Forman; Auayporn Nademanee
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

5.  Natural cell-mediated cytotoxicity in cutaneous T-cell lymphomas.

Authors:  B A Neilan; E C Vonderheid; K J O'Neill
Journal:  J Invest Dermatol       Date:  1983-08       Impact factor: 8.551

Review 6.  Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma.

Authors:  Joan Guitart; Scott C Wickless; Yu Oyama; Timothy M Kuzel; Steve T Rosen; Ann Traynor; Richard Burt
Journal:  Arch Dermatol       Date:  2002-10

7.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.

Authors:  Mindi R Walker; Deborah J Kasprowicz; Vivian H Gersuk; Angele Benard; Megan Van Landeghen; Jane H Buckner; Steven F Ziegler
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

8.  Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, haematological and immunological features.

Authors:  M G Bernengo; P Quaglino; M Novelli; N Cappello; G C Doveil; F Lisa; A De Matteis; M T Fierro; A Appino
Journal:  Ann Oncol       Date:  1998-08       Impact factor: 32.976

9.  Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications.

Authors:  M A Wasik; E C Vonderheid; R D Bigler; R Marti; S R Lessin; M Polansky; M E Kadin
Journal:  Arch Dermatol       Date:  1996-01

10.  Aberrant expression of T-plastin in Sezary cells.

Authors:  Ming-wan Su; Irene Dorocicz; Wieslawa H Dragowska; Vincent Ho; Gang Li; Nicolas Voss; Randy Gascoyne; Youwen Zhou
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

View more
  18 in total

Review 1.  Tissue-specific homing of immune cells in malignant skin tumors.

Authors:  Hajnalka Jókai; Márta Marschalkó; Judit Csomor; József Szakonyi; Orsolya Kontár; Gábor Barna; Sarolta Kárpáti; Péter Holló
Journal:  Pathol Oncol Res       Date:  2012-04-24       Impact factor: 3.201

2.  Genetic markers associated with progression in early mycosis fungoides.

Authors:  V E Johnson; E C Vonderheid; A D Hess; C M Eischen; L Y McGirt
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-10-31       Impact factor: 6.166

Review 3.  Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).

Authors:  Henry K Wong; Anjali Mishra; Timothy Hake; Pierluigi Porcu
Journal:  Br J Haematol       Date:  2011-08-25       Impact factor: 6.998

Review 4.  Sézary Syndrome: Clinical and Biological Aspects.

Authors:  Rebecca Kohnken; Stephanie Fabbro; Justin Hastings; Pierluigi Porcu; Anjali Mishra
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

5.  Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome.

Authors:  Laura Y McGirt; Christopher Thoburn; Allan Hess; Eric C Vonderheid
Journal:  Photodermatol Photoimmunol Photomed       Date:  2010-08       Impact factor: 3.135

6.  Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.

Authors:  Larisa J Geskin; Oleg E Akilov; Soonyou Kwon; Michael Schowalter; Simon Watkins; Theresa L Whiteside; Lisa H Butterfield; Louis D Falo
Journal:  Cancer Immunol Immunother       Date:  2017-12-04       Impact factor: 6.968

7.  T-plastin (PLS3) gene expression differentiates Sézary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression.

Authors:  N Tang; H Gibson; T Germeroth; P Porcu; H W Lim; H K Wong
Journal:  Br J Dermatol       Date:  2009-11-30       Impact factor: 9.302

8.  CD20, AIF-1, and TGF-beta in graft-versus-host disease: a study of mRNA expression in histologically matched skin biopsies.

Authors:  Julie M Wu; Christopher J Thoburn; Joshua Wisell; Evan R Farmer; Allan D Hess
Journal:  Mod Pathol       Date:  2010-02-26       Impact factor: 7.842

9.  Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.

Authors:  Christopher G Kanakry; Allan D Hess; Christopher D Gocke; Christopher Thoburn; Ferdynand Kos; Christian Meyer; Janet Briel; Leo Luznik; B Douglas Smith; Hyam Levitsky; Judith E Karp
Journal:  Blood       Date:  2010-10-08       Impact factor: 22.113

10.  Paucity of intraepidermal FoxP3-positive T cells in cutaneous T-cell lymphoma in contrast with spongiotic and lichenoid dermatitis.

Authors:  David A Wada; Ryan A Wilcox; Roger H Weenig; Lawrence E Gibson
Journal:  J Cutan Pathol       Date:  2009-08-07       Impact factor: 1.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.